VDPHL01 is an investigational oral drug developed by Veradermics for androgenetic alopecia (pattern hair loss). Unlike hormonal treatments, it does not affect the hormonal system, reducing the likelihood of side effects such as decreased libido and erectile dysfunction, which are common among patients taking finasteride.
VDPHL01 is an extended-release oral formulation of minoxidil — a well-established, non-hormonal hair-growth agent. It works by improving blood flow to the hair follicle and prolonging the active growth phase; it does not act on hormones such as DHT. Its proprietary extended-release technology releases the drug slowly and steadily, sustaining the hair-growth effect while avoiding the plasma peaks behind the cardiac side effects of standard (immediate-release) oral minoxidil.
Sources: Veradermics Corporate Presentation (May 2026); Study ‘302’ topline results (April 2026).
Key facts
- Therapeutic area — androgenetic alopecia (AGA), in men and women.
- Formulation — extended-release oral minoxidil tablet; 8.5 mg once or twice daily in the male trials.
- Mechanism — non-hormonal; extended-release minoxidil that boosts follicular blood flow and prolongs the hair-growth phase, without affecting DHT or other hormones.
- Clinical stage — Phase 2/3 Study ‘302’ (males) reported positive topline results (April 2026); confirmatory Study ‘304’ readout expected H2 2026; female Study ‘306’ actively recruiting (NCT06724614).
- Regulatory status — not approved, not available for purchase.
- Developer — Veradermics Inc. (USA); NYSE: MANE.
Sources: Business Wire (27 Apr 2026); ClinicalTrials.gov NCT06724614.
Who may benefit in future
- Adults with early- to mid-stage AGA seeking a non-hormonal oral therapy.
- People who stopped finasteride or dutasteride because of sexual or mood-related side effects.
- Patients who prefer a once- or twice-daily oral tablet over messy daily topical applications.
What’s next?
Topline results for the male Phase 2/3 trial (Study ‘302’) were positive (April 2026); confirmatory data from Study ‘304’ are expected in H2 2026. Follow the detailed timeline on the Clinical Trials page and see comparative data on the Treatment Comparison page.